Tea Consumption Can Lower Mortality in Chronic Kidney Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 17, 2025 -- Tea consumption offers protective effects on mortality among patients with chronic kidney disease (CKD), according to a study published online Jan. 13 in Renal Failure.
Jin Li, Ph.D., from the Guangzhou University of Chinese Medicine in China, and colleagues examined the long-term impact of tea consumption among 17,575 patients with CKD from the National Health and Nutrition Examination Survey for 1999 to 2018.
The researchers found there were 5,835 deaths during follow-up, including 1,823 cardiovascular-related deaths. Compared with never drinking tea, consuming up to four cups of tea per day was significantly associated with lower all-cause mortality among patients with CKD stage 1 to 2 (hazard ratio, 0.89; 95 percent confidence interval, 0.80 to 0.99; P = 0.04), after adjustment for confounding variables; the association between tea consumption and cardiovascular disease (CVD) mortality was not significant (hazard ratio, 0.87; 95 percent confidence interval, 0.72 to 1.05; P = 0.15). There was a dose-response effect observed, with the risks for all-cause mortality mitigated by consuming up to three to five cups of tea per day, especially in early CKD stages. In CKD stage 1 to 2, an intake of one cup per day higher of oxidized tea was associated with a 10 percent lower risk for all-cause mortality (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.99; P = 0.03). Replacing one cup of green tea with one cup of oxidized tea was associated with a significantly lower risk for all-cause and CVD mortality (hazard ratios [95 percent confidence intervals], 0.92 [0.86 to 0.98; P = 0.01] and 0.89 [0.80 to 1.00; P < 0.05], respectively) in those with CKD stage 1 to 2.
"We suggested that CKD patients limit their daily intake of tea to no more than four cups, and choose appropriate varieties and flavors, such as oxidized tea and sugar-free tea," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-18 12:00
Read more
- U.S. Food and Drug Administration Issues Complete Response Letter for the Glepaglutide New Drug Application for the Treatment of Short Bowel Syndrome
- Prebiopsy MRI Oncologically Safe for Suspected Prostate Cancer
- Many in Need of Substance Use Disorder Treatment Not Receiving It
- Fecal Transplants May Help People Who Have Diabetes, Gut Issues, Study Says
- Multilingual Children with Autism Show Improved Cognitive Function
- Odds of Metabolic Disease Lower With Fast Subjective Walking Speed in Patients With Obesity
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions